Alector Inc. Common Stock (ALEC)
Stock · NASDAQ · Health Care
$1.84as of 10/16/2026
Price chart
Active signals
ALEC Signal Track Record
How signals performed across all stocks →What ALEC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -6.2% | 43% | October 5, 2026 |
| Bollinger Band Breakout | 25 | -4.5% | 36% | September 2, 2026 |
| Bollinger Band Breakdown | 22 | -3.1% | 45% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -16.5% | 9% | October 5, 2026 |
| Any 20-session window (baseline) | -1.4% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALEC
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL0…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 103
- Website
- alector.com
Fundamentals
- 1-day range
- $1.8$2.18
- Market cap
- $203.18M
- P/E (trailing)
- —
- P/E (forward)
- -2.51
- EPS (trailing)
- $-1.09
- Dividend yield
- —
- Beta
- 0.65
- Avg. volume
- 3.04M
How Alector Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Alector Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALECAlector Inc. Common Stock$1.84▼ 3.66%Market cap $203.18MP/E —$1.09$3.4
- PLXProtalix BioTherapeutics Inc. (DE) Common Stock$2.62▼ 2.96%Market cap $196.59MP/E 11.27$1.6$3.19
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
- DTILPrecision BioSciences Inc. Common Stock$5.77▼ 6.48%Market cap $191.45MP/E —$3.53$9.62
- VYGRVoyager Therapeutics Inc. Common Stock$1.9▼ 7.77%Market cap $189.12MP/E —$2.33$5.55
- CGENCompugen Ltd. Ordinary Shares$1.96▼ 5.77%Market cap $217.54MP/E 5.59$1.43$3.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALEC Alector Inc. Common Stock | $203.18M | — | $1.84 | ▼ 3.66% | $1.09$3.4 |
| PLX Protalix BioTherapeutics Inc. (DE) Common Stock | $196.59M | 11.27 | $2.62 | ▼ 2.96% | $1.6$3.19 |
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
| DTIL Precision BioSciences Inc. Common Stock | $191.45M | — | $5.77 | ▼ 6.48% | $3.53$9.62 |
| VYGR Voyager Therapeutics Inc. Common Stock | $189.12M | — | $1.9 | ▼ 7.77% | $2.33$5.55 |
| CGEN Compugen Ltd. Ordinary Shares | $217.54M | 5.59 | $1.96 | ▼ 5.77% | $1.43$3.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alector Prices $75.03M Common Stock Offering Of 36.6M Shares At $2.05/Sharebenzinga · 10/16/2026
- Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell RightsYahoo · 10/10/2026
- Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled PipelineYahoo · 10/7/2026
- Morgan Stanley Maintains Underweight on Alector, Raises Price Target to $3Benzinga · 10/6/2026
- Alector shares up after sealing $1.27bn Roche Parkinson’s disease license dealYahoo · 10/6/2026
- Which stocks are most active on Monday?ChartMill · 10/5/2026
- BC-Most Active StocksYahoo · 10/5/2026
- Alector Signs $1.27 Billion Genentech License Agreement for Parkinson’s Disease ProgramYahoo · 10/5/2026
- Optogenics researchers win a Nobel Prize; Roche bets on Alector brain drugYahoo · 10/5/2026
Insider Activity
Insider Actions →- Grace Wong-Sarad · September 4, 2026 · Sale3.6K @ $2.51
- Grace Wong-Sarad · September 3, 2026 · Sale5.2K @ $2.67
- Arnon Rosenthal · September 3, 2026 · Sale72.6K @ $2.66
- Neil Lindsay Berkley · September 3, 2026 · Sale29.3K @ $2.66
- Grace Wong-Sarad · September 2, 2026 · Sale656 @ $2.75
- Arnon Rosenthal · August 19, 2026 · Gift350.0K
- Arnon Rosenthal · August 19, 2026 · Gift1.05M
- Grace Wong-Sarad · July 9, 2026 · Grant20.0K
- Kristine Yaffe · June 17, 2026 · Grant9.4K
- Kristine Yaffe · June 17, 2026 · Grant28.7K
- Elizabeth A. Garofalo · June 17, 2026 · Grant9.4K
- Elizabeth A. Garofalo · June 17, 2026 · Grant28.7K
- Paula Hammond · June 17, 2026 · Grant9.4K
- Paula Hammond · June 17, 2026 · Grant28.7K
- Mark Altmeyer · June 17, 2026 · Grant9.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 85.39M
- Total value held
- $174.58M
- Institutional holders
- 133
- Unknown10.00M
- Unknown7.74M
- Unknown4.04M
- Unknown3.89M
- Unknown3.68M
- Unknown3.55M
- Unknown3.33M
- Unknown3.20M
- Unknown2.94M
- Unknown2.82M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Alector (ALEC) sees purchases by NVIDIA and Merck
Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.
Alector (ALEC) sees purchases by NVIDIA and Merck. Recent filings show that NVIDIA and Merck have added positions in Alector. The involvement of these large technology and pharmaceutical firms may draw attention to the biotech company. The stock is currently trading near its 10‑touch support level of $1.47. Market participants may watch how this institutional interest aligns with the company's valuation.